This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better-informed drug policy and action.

Adopted unanimously by the agency’s key stakeholders in 2016, the strategy is the result of a year-long, in-depth analysis of the environment in which the EMCDDA operates.

This analysis focused, in particular, on customer needs and a critical review of our internal capacity to meet them.

Professionals, academics or experts from European Neighbourhood Policy (ENP) countries (1) will have an opportunity to participate in the European Drugs Winter and Summer Schools this year, thanks to 10 bursaries being offered through the EU4Monitoring Drugs (EU4MD) project.

The University Institute of Lisbon (ISCTE-IUL) and the EMCDDA are offering the two courses following the success of the European Drugs Summer School (EDSS) in 2020, taught remotely due to the COVID-19 pandemic.

The European Drugs Winter School (EDWS), taking place online from 1–12 March 2021, will focus on the theme...

The Global Synthetic Drugs Assessment 2020 provides an analysis of the global synthetic drugs market.

• The first part of this report provides options for responses to counter the synthetic drug problem.
• The second part presents a global thematic analysis of the key trends and emerging developments of the synthetic drugs market as well as the recent trends in the manufacture of synthetic drugs, including the effects of the COVID-19 pandemic.
• The third part provides the key findings of the synthetic drug situation in the different regions of the world.

Global Synthetic Drugs Assessment

Reitox is the European information network on drugs and drug addiction created at the same time as the EMCDDA.

Members of the Reitox network are designated national institutions or agencies responsible for data collection and reporting on drugs and drug addiction. These institutions are called 'national focal points' or 'national drug observatories'.

This report highlights the responses taken by the EMCDDA's Reitox network of national focal points to the COVID-19 crisis and describes the challenges met by the organisations and the strategies produced to overcome these challenges.

This fact sheet provides up-to-date information and guidance on the links between alcohol and a range of cancers, including some of the most common types, such as female breast cancer and colorectal cancer, for those involved in designing and implementing policies that affect public health.

It sets out policy options to reduce the alcohol-attributable cancer burden within the WHO European Region, making clear that there is strong evidence that the implementation of cost-effective alcohol control policies including pricing policies (or policies that increase the price of alcohol) will...

European Drug Report 2020

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets 
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2020 European Drug Report, our annual overview of the drug situation in Europe, launched on 22 September.

This report, available in 24 languages, presents a summary of the main findings of the 'European Drug Report 2020: Trends and Developments the EMCDDA’s latest analysis...